ARCHIVES

Phase III Ramucirumab Trial Fails Primary Endpoint of PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 10 | October 25, 2013

Download PDF Visit The Full Archive

Related Articles

ONS Forms More Special Interest Groups For Members

May 11, 1990

In Brief: No Such Thing As Premature Data, Fisher Says- Only Immature Evaluation, Premature Application

June 20, 1980

Monroe Wall, Co-Discoverer Of Taxol, Camptothecin, Dead At 85

July 12, 2002

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

September 26, 2014

Cancer Act Renewals Marked By Disputes Over NCI Authorities

October 5, 1990

Four RFAs Released For RM Program

November 6, 1981